专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08222374B2 IL-21 antagonists 有权
标题翻译： IL-21拮抗剂
公开(公告)号：US08222374B2
公开(公告)日：2012-07-17
申请号：US13037585
申请日：2011-03-01
申请人： Pallavur V. Sivakumar , Stephen R. Jaspers
发明人： Pallavur V. Sivakumar , Stephen R. Jaspers
IPC分类号： A61K39/395 , C07K16/24 , C12P21/08
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
摘要翻译：鉴定结合IL-21蛋白的单克隆抗体。这些抗体用于鉴定结合中和IL-21活性的IL-21蛋白的区域。描述了杂交瘤和产生抗IL-21单克隆抗体的方法。单克隆抗体可用于治疗IL-21介导的疾病，其可能包括自身免疫性和炎性疾病如胰腺炎，I型糖尿病（IDDM），格雷夫斯病，炎性肠病（IBD），克罗恩病，溃疡性结肠炎，肠易激综合征综合征，多发性硬化症，类风湿性关节炎，憩室病，系统性红斑狼疮，牛皮癣，强直性脊柱炎，硬皮病，系统性硬化症，银屑病关节炎，骨关节炎，特应性皮炎，白癜风，移植物抗宿主病（GVHD），皮肤T细胞淋巴瘤，干燥综合征，肾小球性肾炎，IgA肾病，移植排斥反应，特应性皮炎，抗磷脂综合征，哮喘和其他自身免疫性疾病。

2. 发明授权

US07592427B2 Antibodies to IL-21 receptor 有权
标题翻译： IL-21受体的抗体
公开(公告)号：US07592427B2
公开(公告)日：2009-09-22
申请号：US11564001
申请日：2006-11-28
申请人： Pallavur V. Sivakumar , Stephen R. Jaspers
发明人： Pallavur V. Sivakumar , Stephen R. Jaspers
IPC分类号： C12P21/08
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2Rγ; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.
摘要翻译： IL-21受体的单克隆抗体和包含IL-21受体的多聚复合物; 包括针对异二聚体受体的单克隆抗体，IL-21 / IL-2Rγ; 已经准备好了本发明还描述了产生所述抗体的方法。而且，本发明还描述了一种包括使用所述抗体抑制免疫应答的治疗方法。

3. 发明授权

US07923539B2 IL-21 antagonists 有权
标题翻译： IL-21拮抗剂
公开(公告)号：US07923539B2
公开(公告)日：2011-04-12
申请号：US12179003
申请日：2008-07-24
申请人： Pallavur V. Sivakumar , Stephen R. Jaspers
发明人： Pallavur V. Sivakumar , Stephen R. Jaspers
IPC分类号： C12P21/08 , A61K39/395 , C07K16/24
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
摘要翻译：鉴定结合IL-21蛋白的单克隆抗体。这些抗体用于鉴定结合中和IL-21活性的IL-21蛋白的区域。描述了杂交瘤和产生抗IL-21单克隆抗体的方法。单克隆抗体可用于治疗IL-21介导的疾病，其可能包括自身免疫性和炎性疾病如胰腺炎，I型糖尿病（IDDM），格雷夫斯病，炎性肠病（IBD），克罗恩病，溃疡性结肠炎，肠易激综合征综合征，多发性硬化症，类风湿性关节炎，憩室病，系统性红斑狼疮，牛皮癣，强直性脊柱炎，硬皮病，系统性硬化症，银屑病关节炎，骨关节炎，特应性皮炎，白癜风，移植物抗宿主病（GVHD），皮肤T细胞淋巴瘤，干燥综合征，肾小球性肾炎，IgA肾病，移植排斥反应，特应性皮炎，抗磷脂综合征，哮喘和其他自身免疫性疾病。

4. 发明申请

US20090075341A1 IL-21 ANTAGONISTS 有权
标题翻译： IL-21拮抗剂
公开(公告)号：US20090075341A1
公开(公告)日：2009-03-19
申请号：US12179003
申请日：2008-07-24
申请人： Pallavur V. Sivakumar , Stephen R. Jaspers
发明人： Pallavur V. Sivakumar , Stephen R. Jaspers
IPC分类号： C12P21/08 , C07K16/24 , C12N5/06
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
摘要翻译：鉴定结合IL-21蛋白的单克隆抗体。这些抗体用于鉴定结合中和IL-21活性的IL-21蛋白的区域。描述了杂交瘤和产生抗IL-21单克隆抗体的方法。单克隆抗体可用于治疗IL-21介导的疾病，其可能包括自身免疫性和炎性疾病如胰腺炎，I型糖尿病（IDDM），格雷夫斯病，炎性肠病（IBD），克罗恩病，溃疡性结肠炎，肠易激综合征综合征，多发性硬化症，类风湿性关节炎，憩室病，系统性红斑狼疮，牛皮癣，强直性脊柱炎，硬皮病，系统性硬化症，银屑病关节炎，骨关节炎，特应性皮炎，白癜风，移植物抗宿主病（GVHD），皮肤T细胞淋巴瘤，干燥综合征，肾小球肾炎，IgA肾病，移植物宿主病，移植排斥反应，特应性皮炎，抗磷脂综合征，哮喘和其他自身免疫性疾病。

5. 发明授权

US08790643B2 Methods for treating disease using an anti-IL-21 receptor antibody 有权
标题翻译：使用抗IL-21受体抗体治疗疾病的方法
公开(公告)号：US08790643B2
公开(公告)日：2014-07-29
申请号：US12941354
申请日：2010-11-08
申请人： Pallavur V. Sivakumar , Stephen R. Jaspers
发明人： Pallavur V. Sivakumar , Stephen R. Jaspers
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2Rγ; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.
摘要翻译： IL-21受体的单克隆抗体和包含IL-21受体的多聚复合物; 包括对异二聚体受体的单克隆抗体，IL-21 / IL-2Rγ; 已经准备好了本发明还描述了产生所述抗体的方法。而且，本发明还描述了一种包括使用所述抗体抑制免疫应答的治疗方法。

6. 发明授权

US09388241B2 Anti-human IL-21 antibodies 有权
标题翻译：抗人IL-21抗体
公开(公告)号：US09388241B2
公开(公告)日：2016-07-12
申请号：US13492315
申请日：2012-06-08
申请人： Pallavur V. Sivakumar , Stephen R. Jaspers
发明人： Pallavur V. Sivakumar , Stephen R. Jaspers
IPC分类号： A61K39/395 , C07K16/22 , C07K16/24 , C07K16/18 , A61K39/00
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
摘要翻译：鉴定结合IL-21蛋白的单克隆抗体。这些抗体用于鉴定结合中和IL-21活性的IL-21蛋白的区域。描述了杂交瘤和产生抗IL-21单克隆抗体的方法。单克隆抗体可用于治疗IL-21介导的疾病，其可能包括自身免疫性和炎性疾病如胰腺炎，I型糖尿病（IDDM），格雷夫斯病，炎性肠病（IBD），克罗恩病，溃疡性结肠炎，肠易激综合征综合征，多发性硬化症，类风湿性关节炎，憩室病，系统性红斑狼疮，牛皮癣，强直性脊柱炎，硬皮病，系统性硬化症，银屑病关节炎，骨关节炎，特应性皮炎，白癜风，移植物抗宿主病（GVHD），皮肤T细胞淋巴瘤，干燥综合征，肾小球性肾炎，IgA肾病，移植排斥反应，特应性皮炎，抗磷脂综合征，哮喘和其他自身免疫性疾病。

7. 发明申请

US20110081340A1 METHODS FOR TREATING DISEASE USING AN ANTI-IL-21 RECEPTOR ANTIBODY 有权
标题翻译：使用抗IL-21受体抗体治疗疾病的方法
公开(公告)号：US20110081340A1
公开(公告)日：2011-04-07
申请号：US12941354
申请日：2010-11-08
申请人： Pallavur V. Sivakumar , Stephen R. Jaspers
发明人： Pallavur V. Sivakumar , Stephen R. Jaspers
IPC分类号： A61K39/395 , A61P29/00 , A61P37/02 , A61P17/06 , A61P19/02 , A61P37/06 , A61P25/28 , A61P1/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2Rγ; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.
摘要翻译： IL-21受体的单克隆抗体和包含IL-21受体的多聚复合物; 包括对异二聚体受体的单克隆抗体，IL-21 / IL-2Rγ; 已经准备好了本发明还描述了产生所述抗体的方法。而且，本发明还描述了一种包括使用所述抗体抑制免疫应答的治疗方法。

8. 发明申请

US20100008915A1 METHODS FOR TREATING DISEASE USING AN ANTI-IL-21 RECEPTOR ANTIBODY 审中-公开
标题翻译：用抗IL-21受体抗体治疗疾病的方法
公开(公告)号：US20100008915A1
公开(公告)日：2010-01-14
申请号：US12541544
申请日：2009-08-14
申请人： Pallavur V. Sivakumar , Stephen R. Jaspers
发明人： Pallavur V. Sivakumar , Stephen R. Jaspers
IPC分类号： A61K39/395 , A61P37/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2Rγ; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.
摘要翻译： IL-21受体的单克隆抗体和包含IL-21受体的多聚复合物; 包括针对异二聚体受体的单克隆抗体，IL-21 / IL-2Rγ; 已经准备好了本发明还描述了产生所述抗体的方法。而且，本发明还描述了一种包括使用所述抗体抑制免疫应答的治疗方法。

9. 发明申请

US20130273000A1 METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 审中-公开
标题翻译：使用IL-28和IL-29治疗病毒感染的方法
公开(公告)号：US20130273000A1
公开(公告)日：2013-10-17
申请号：US13616688
申请日：2012-09-14
申请人： Kevin M. Klucher , Pallavur V. Sivakumar , Wayne R. Kindsvogel , Katherine E. Henderson
发明人： Kevin M. Klucher , Pallavur V. Sivakumar , Wayne R. Kindsvogel , Katherine E. Henderson
IPC分类号： A61K47/48
CPC分类号： A61K47/60 , A61K38/20 , A61K38/21 , C07K14/54 , Y02A50/385 , Y02A50/393
摘要： IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
摘要翻译：已经显示IL-28A，IL-28B，IL-29及其某些突变体对病毒物种的光谱具有抗病毒活性。特别感兴趣的是在感染肝脏的病毒（例如乙型肝炎病毒和丙型肝炎病毒）上显示的抗病毒活性。此外，IL-28A，IL-28B，IL-29及其突变体在用干扰素治疗观察到的造血细胞上不表现出一些抗增殖活性。没有伴随干扰素治疗的免疫抑制作用，IL-28A，IL-28B和IL-29可用于治疗免疫功能低下的病毒感染患者。

10. 发明申请

US20130022571A1 METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 CYSTEINE MUTANTS 有权
公开(公告)号：US20130022571A1
公开(公告)日：2013-01-24
申请号：US13606176
申请日：2012-09-07
申请人： Kevin M. Klucher , Wayne R. Kindsvogel , Pallavur V. Sivakumar , Katherine E. Henderson
发明人： Kevin M. Klucher , Wayne R. Kindsvogel , Pallavur V. Sivakumar , Katherine E. Henderson
IPC分类号： A61K38/20 , A61P31/14
CPC分类号： A61K38/20 , A61K38/21 , A61K38/212 , A61K38/57 , A61K47/60 , C07K14/54 , A61K2300/00
摘要： IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式